These ASX innovators could be the market’s next big winners

The Australian share market has had its fair share of volatility this year, but one thing hasn’t changed.

That is that innovation still creates long-term value for investors.

So, with a number of innovators trading sharply lower than their highs, now could be an opportune time to snap up their shares. Here are three that analysts rate as buys:

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix is rapidly becoming one of Australia’s most exciting biotechnology stories.

Its flagship product, Illuccix, which is a radiopharmaceutical imaging agent for prostate cancer, has seen explosive global uptake. The company is now generating strong revenue growth and reinvesting heavily into its pipeline of diagnostic and therapeutic cancer treatments.

With these products progressing through clinical trials, Telix has multiple shots on goal, and each one comes with transformative commercial potential. And while its failure to gain FDA approval at the first application has dented investor sentiment this year, most analysts believe it is a case of when and not if approval is given.

Bell Potter remains very positive and has put an buy rating and $23.00 price target on its shares.

Pro Medicus Ltd (ASX: PME)

Another ASX innovator that could be a buy is Pro Medicus. It is one of the ASX’s most impressive growth stories.

Pro Medicus’ Visage imaging platform is used by leading hospitals and radiology groups across the United States, providing ultra-fast image viewing and analysis for radiologists.

The company’s margins are exceptional, its revenue is highly recurring, and its contract wins are becoming larger and more frequent. Many medical centres are still in the early stages of moving to cloud-based imaging, which gives Pro Medicus a long runway of structural growth.

With a capital-light business model, expanding market share, and deep competitive moats, Pro Medicus is uniquely positioned to benefit from the global demand for faster, smarter, AI-assisted medical imaging.

Bell Potter is also bullish on this one and has a buy rating and $320.00 price target on its shares.

WiseTech Global Ltd (ASX: WTC)

A third ASX innovator to look at is WiseTech.

It is a software provider for global logistics companies, with its CargoWise platform deeply embedded into freight forwarding, customs, and shipping operations worldwide.

Despite recent share price weakness, WiseTech continues to grow revenue, integrate acquisitions, and win major enterprise customers. Global supply chains are becoming more digitised, and regulatory environments are getting more complex. This is a trend that strengthens the need for WiseTech’s mission-critical software and positions its for growth over the long term.

UBS is bullish on this ASX stock and has put a buy rating and $130.00 price target on its shares.

The post These ASX innovators could be the market’s next big winners appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Forget Zip shares: Here’s why Xero and WiseTech are better tech bets for 2026
• 5 most-traded Australian shares last week
• 2 ASX 200 tech stocks racing higher on big news
• These are the 10 most shorted ASX shares

Motley Fool contributor James Mickleboro has positions in Pro Medicus and WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals and WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool Australia has recommended Pro Medicus and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.